The antimalarial drug, hydroxychloroquine has been previously announced as a ‘game-changer’ in treating COVID-19 patients. But the recent studies show contrasting outcomes have been seen in COVID-19 patients. Some patients claim that this drug improved their condition while others blame that it brings cure for the adverse reactions.
Since U.S. President Donald Trump upheld the medication hydroxychloroquine as a potential treatment for COVID-19 patients, numerous lupus patients have attempted to get the medication while many of them state they can’t live without.
President Donald Trump called chloroquine and hydroxychloroquine a “game-changer.” He said, “I feel good about it.” But most of the doctors are not so sure about its effectiveness against COVID-19.
Philip M. Carlucci is from New York University Grossman School of Medicine in New York City, he and his colleagues collected data from electronic medical records for COVID-19 patients. Hospital outcomes were analyzed for more than four hundred patients who received azithromycin and hydroxychloroquine versus more than five hundred patients who received azithromycin and hydroxychloroquine alone.
The CDC reports that no drug or vaccine is approved by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients. The National Institutes of Health (NIH) have published guidelines for medical management of COVID-19 that will update all therapeutic interventions that are approved for use by the Food and Drug Administration (FDA).
The analysts found that the zinc sulfate addition did not change the length of hospitalization, duration of ventilation, or span of intensive care unit ( ICU). Zinc sulfate increased the frequency of patients being discharged home and decreased the requirement for ventilation, admission to the intensive care unit (ICU), and mortality or move to hospice for patients not admitted to the intensive care unit (ICU) in univariate analyses.
Zinc itself has antiviral properties. Past investigations have suggested that it could lessen the time individuals experience from the common cold. Joseph Rahimian is an infectious disease specialist. He says that the effectiveness of zinc increases when combined with hydroxychloroquine in treating COVID-19 patients. He includes that it could be the essential component assaulting the infection and hydroxychloroquine could serve as an agent that transport the zinc into the cells.
The Food and Drug Administration issued a warning that the drugs chloroquine and hydroxychloroquine that are repeatedly promoted by President Donald Trump should be used only for clinical trials. These drugs can cause risky variation in heart rhythm in COVID-19 patients, and ought to be used distinctly in clinical trials or emergency clinics where patients can be closely observed for heart issues.
Many medical societies including the American Thoracic Society, the American College of Cardiology, and the Infectious Diseases Society of America have warned risks of using these drugs to treat COVID-19 patients outside of a clinical trial or without close monitoring.
Many doctors are using hydroxychloroquine for the treatment of Covid-19, the disease caused by coronavirus because no vaccine or any other effective treatment is available against it.
The FDA statement said,
“The F.D.A. is aware of reports of serious heart rhythm problems in patients with Covid-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin”
So findings remained significant for more frequency of being discharged and decrease in mortality or move to hospice after modification for the time at which zinc sulfate was added to the convention.
The authors say that the present study should not be used to control clinical practice. Their perceptions support the inception of future randomized clinical trials exploring zinc sulfate against COVID-19 patients.